Skip to main content

Table 1 Clinical profile of the CU A−, CU A+, MCI-AD and AD dementia patients

From: Sex-specific associations of matrix metalloproteinases in Alzheimer’s disease

 

CU A−

CU A+

MCI-AD

AD dementia

χ2/F (df)

P2)

N

74

26

50

206

  

Female n (%)

31 (41.9)

15 (57.7)

27 (54.0)

121 (58.7)

6.35

0.10

Age

72.2 (6.1)

72.2 (5.9)

71.5 (4.7)

70.0 (6.7)

2.64

0.45d

APOE ε4 n (%)f

20 (28.6)

16 (69.6)a

40 (85.1)a

139 (76.8)a

61.63

< 0.01

Education

14.8 (3.5)

12.4 (3.1)a

13.1 (3.8)

12.2 (3.7)a

8.95 (3)

< 0.01

MMSE

29.2 (1.0)

29.0 (0.8)

26.3 (3.3)a, b

22.2 (4.3)a−c

192.1

< 0.01d

CDT

4.8 (0.5)

4.7 (0.6)

4.1 (1.0)

3.3 (1.5)

33.45 (4)

0.94

CDR-SB

NA

NA

1.9 (1.4)

4.4 (2.0)c

 

< 0.01e

CSF Aβ42

806.7 (137.6)

443.2 (76.2)

537.9 (92.0)

512.4 (101.9)

 

NA

CSF p-tau

57.4 (17.7)

58.0 (22.2)

86.6 (36.2)

98.8 (43.4)

 

NA

T + 

26 (35.1)

11 (42.3)

28 (56.0)a

138 (67.0)a, b

25.14

< 0.01

CSF t-tau

349.8 (123.2)

365.8 (170.9)

627 (284.6)

766.4 (378.6)

 

NA

N + 

32 (43.3)

11 (42.3)

35 (70.0)a, b

158 (76.7)a, b

34.58

< 0.01

  1. Data reported is mean (standard deviation) unless otherwise indicated. P-values are for comparisons between all four groups using χ2 (categorical variables) or ANOVA (continuous variables), unless otherwise specified. Significant differences in bold. Biomarkers are given in pg/mL. Comparison of biomarker levels between CU controls and patients is not applicable as different cut-offs were applied
  2. aSignificantly different from the CU A− group; bSignificantly different from the CU A + group; cSignificantly different form the MCI-AD group; dKruskal–Wallis test; eindependent samples t-test; fn = 321, 35 missing genotype. A+: biomarkers positive for Aβ pathology, amyloid-β, AD Alzheimer’s disease, ANOVA analysis of variance, APOE apolipoprotein E, CDR-SB clinical dementia rating scale sum of boxes, CDT clock drawing test, CSF cerebrospinal fluid, CU cognitively unimpaired, MCI mild cognitive impairment, MMSE mini-mental status examination, N + biomarkers positive for neurodegeneration, p-tau phosphorylated tau, T + biomarkers positive for tau pathology, t-tau total tau